Verinurad

Research use only, not for human use.

A highly potent and specific URAT1 inhibitor with IC50 of 25 nM.

A highly potent and specific URAT1 inhibitor with IC50 of 25 nM; displays 200-fold lower affinity for the related URAT1 homologs OAT4 and OAT1; reduces the sUA by up to 60% with a single 40?mg dose in healthy human volunteers, and increases the FEUA in a dose-dependent manner with EC50 of 22 nM; currently in phase 2 trials for the treatment of gout and asymptomatic hyperuricemia.Gout Phase 2 Clinical(In Vitro):Verinurad inhibits the transport activity of human URAT1 in a dose-dependent manner, at high potency with an IC50 of 25?nM.

Verinurad inhibits the transport activity of human URAT1 in a dose-dependent manner, at high potency with an IC50 of 25?nM .

——

RDEA-3170

Membrane Transporter/Ion Channel

URAT1

URAT1

Inflammation/Immunology

Gout

1352792-74-5

348.4182

C20H16N2O2S

>98% (HPLC)

10 mM in DMSO

CC(C)(SC1=C(C2=C3C=CC=CC3=C(C#N)C=C2)C=NC=C1)C(O)=O

Propanoic acid, 2-[[3-(4-cyano-1-naphthalenyl)-4-pyridinyl]thio]-2-methyl-

(-20℃)

With Ice Pack

≥ 2 years